Our Blog

May 4, 2015

Dr. Shantanu Gaur presents at SAGES 2015

Allurion Technologies co-founder and Chief Scientific Officer Dr. Shantanu Gaur presented an update on the Elipse Balloon at the 2015 Society for American Gastrointestinal and Endoscopic Surgeons (SAGES) surgeons. We would like to thank the organizers of SAGES for a wonderful conference!

April 21, 2015

Gastric Balloon Review

Allurion co-founders Drs. Shantanu Gaur and Samuel Levy and Senior Medical Advisor Dr. Ram Chuttani recently co-authored an article entitled Balancing Risk and Reward: A Critical Review of the Intragastric Balloon for Weight Loss now in press at Gastrointestinal Endoscopy. The goal of this review was to answer 3 questions: How much weight is lost in gastric balloon therapy and is weight loss time-dependent? After gastric balloon therapy ends, how much weight loss is maintained? If adverse events occur, when do they occur in the course of gastric balloon therapy? The review concludes that 80% of the weight lost during gastric balloon therapy…

April 1, 2015

Repeat Gastric Balloon Therapy

Gastric balloons are sometimes criticized for being short-term therapies that lead to rapid but temporary weight loss. A previous post explores a recent study that demonstrates similar long-term outcomes and weight maintenance whether weight is lost rapidly or gradually. However, in some instances, an individual may desire repeat gastric balloon therapy to either continue losing weight or assist in weight maintenance. Is this possible? Repeat gastric balloon therapy has been studied and demonstrated to be safe and effective. In two separate studies, Dr. Alfredo Genco and Dr. Gontrand Lopez-Nava report that individuals who receive two balloons with a 1 month balloon-free period lost significantly…

April 1, 2015

Elipse Gastric Balloon Featured in WebMD

Allurion’s Elipse was recently featured in WebMD’s Future of Health series in an article entitled “The Next Generation of Weight Loss.” Click here to see the story!

March 16, 2015

Allurion co-founders featured in LeadDoc

Allurion Technologies co-founders Shantanu Gaur and Samuel Levy were featured in the latest edition of Lead Doc – the online journal for emerging physician leaders. Click here to read their story!

February 28, 2015

Slow and Steady Doesn’t Win the Race: It’s a Tie

A recently published paper in Lancet Diabetes and Endocrinology challenges the widely held notion that gradual weight loss is associated with better long-term outcomes than rapid weight loss. Purcell and colleagues randomized 200 people to either a rapid (12 weeks) or gradual (36 weeks) weight loss program (Phase 1) and then followed those who lost at least 12.5% of their weight for over 3 years to assess long-term outcomes (Phase 2). They concluded the following: After nearly 3 years of follow-up, people in both groups maintained ~30% of the weight they had lost (see figure) 81% of people in the rapid…

February 3, 2015

Are gastric balloons effective?

The answer is yes: gastric balloons are effective. Multiple randomized, controlled trials have compared gastric balloon therapy to diet and lifestyle modification and have concluded that gastric balloons are more effective. Here are a few examples: Fuller et al. 2013 showed that 6 months of gastric balloon therapy led to an average of 14kg (31lbs) of weight loss compared to 4.8kg (10.5lbs) from lifestyle modification alone. The weight loss difference remained statistically significant after 12 months. Genco et al. 2006 showed that 3 months of gastric balloon therapy led to an average reduction of 5 more BMI points than lifestyle modification…

January 21, 2015

Patient Preference for Weight Loss Devices

The US Food and Drug Administration (FDA) recently published an article in Surgical Endoscopy that reports results of a survey conducted on patient preference for weight loss devices. The survey quantifies the risk-benefit analysis many patients conduct before deciding on a weight loss therapy. This research is part of a laudable, ongoing effort at FDA to incorporate patient preference in regulatory decision-making. Moreover, the research provides very useful quantitative data to support FDA’s risk-benefit paradigm for evaluating new weight loss devices. In fact, this approach was instrumental in the recent approval of the Enteromedics VBLOC device. While the device failed…

January 2, 2015

Bridging the Gap between Perception and Reality: The Role of a Non-Surgical Weight Loss Device

Only 1-2% of patients who qualify for bariatric (i.e. weight loss) surgery end up getting it. A recent study in Obesity by Fatima Stanford, Ted Kyle, Caroline Apovian and colleagues explores why. In a survey of patients with Class I (BMI 30-34.9), Class II (BMI 35.0-39.9), and Class III (BMI ≥ 40) obesity, the authors found the following: 84% of Class I patients, 63% of Class II patients, and 42% of Class III patients did not perceive themselves as obese 85% of Class I patients and 74% of Class II patients found surgery unacceptable Most patients found surgery unacceptable, because they felt…

December 24, 2014

Gastric Balloon in Private Practice: is close follow-up needed?

Allurion Senior Medical Advisor Dr. Ram Chuttani recently co-authored a paper in Endoscopy on the weight loss outcomes in 815 Dutch men and women receiving the gastric balloon in private practice. Unlike the bulk of the literature on gastric balloons, this paper reports outcomes in a non-academic (i.e. commercial) setting. The results call into question the widely held belief that balloons only work with regular follow-up. Here are the high-level findings: The average weight loss over 3 months was 15.8kg (~35lbs) The average weight loss over 6 months was 20.9kg (~46lbs) The average weight loss over 6 months for patients who had no follow-up was…